Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study

被引:40
作者
Bernasconi, Camilla [1 ]
Pelkonen, Olavi [2 ,10 ]
Andersson, Tommy B. [3 ,4 ]
Strickland, Judy [5 ]
Wilk-Zasadna, Iwona [1 ]
Asturiol, David [1 ]
Cole, Thomas [1 ]
Liska, Roman [1 ]
Worth, Andrew [1 ]
Mueller-Vieira, Ursula [6 ,7 ]
Richert, Lysiane [8 ,9 ]
Chesne, Christophe [9 ]
Coecke, Sandra [1 ]
机构
[1] European Commiss, Joint Res Ctr, Ispra, Italy
[2] Univ Oulu, Res Unit Biomed Pharmacol & Toxicol, Fac Med, Aapistie 5B, FIN-90014 Oulu, Finland
[3] AstraZeneca, Drug Metab & Pharmacokinet Cardiovasc Renal & Met, IMED Biotech Unit, Gothenburg, Sweden
[4] Karolinska Inst, Sect Phannacogenet, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden
[5] Integrated Lab Syst, Res Triangle Pk, NC 27709 USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Discovery Sci, Biberach, Germany
[8] KaLy Cell, 20A,Rue Gen Leclerc, F-67115 Plobsheim, France
[9] Biopredic Int, Parc Activite Breteche Batiment A4, F-35760 St Gregoire, France
[10] Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland
关键词
CYP induction; human hepatocytes; HepaRG; metabolism; in vitro hepatic system; validation; ENDOTHELIN-RECEPTOR ANTAGONIST; CONSTITUTIVE ANDROSTANE RECEPTOR; MULTIPLE-DOSE PHARMACOKINETICS; PREGNANE X RECEPTOR; DRUG-METABOLISM; HUMAN HEPATOCYTES; ARTEMISININ ANTIMALARIALS; HEPARG CELLS; SPECIES-DIFFERENCES; NUCLEAR RECEPTORS;
D O I
10.1016/j.tiv.2019.05.019
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
CYP enzyme induction is a sensitive biomarker for phenotypic metabolic competence of in vitro test systems; it is a key event associated with thyroid disruption, and a biomarker for toxicologically relevant nuclear receptor-mediated pathways. This paper summarises the results of a multi-laboratory validation study of two in vitro methods that assess the potential of chemicals to induce cytochrome P450 (CYP) enzyme activity, in particular CYP1A2, CYP2B6, and CYP3A4. The methods are based on the use of cryopreserved primary human hepatocytes (PHH) and human HepaRG cells. The validation study was coordinated by the European Union Reference Laboratory for Alternatives to Animal Testing of the European Commission's Joint Research Centre and involved a ring trial among six laboratories. The reproducibility was assessed within and between laboratories using a validation set of 13 selected chemicals (known human inducers and non-inducers) tested under blind conditions. The ability of the two methods to predict human CYP induction potential was assessed. Chemical space analysis confirmed that the selected chemicals are broadly representative of a diverse range of chemicals. The two methods were found to be reliable and relevant in vitro tools for the assessment of human CYP induction, with the HepaRG method being better suited for routine testing. Recommendations for the practical application of the two methods are proposed.
引用
收藏
页码:212 / 228
页数:17
相关论文
共 136 条
[61]   Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor [J].
Koehle, Christoph ;
Bock, Karl Walter .
BIOCHEMICAL PHARMACOLOGY, 2009, 77 (04) :689-699
[62]   CAR and PXR: Xenosensors of endocrine disrupters? [J].
Kretschmer, XC ;
Baldwin, WS .
CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 155 (03) :111-128
[63]   Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line [J].
Le Vee, M ;
Jigorel, E ;
Glaise, D ;
Gripon, P ;
Guguen-Guillouzo, C ;
Fardel, O .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 28 (1-2) :109-117
[64]   The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions [J].
Lehmann, JM ;
McKee, DD ;
Watson, MA ;
Willson, TM ;
Moore, JT ;
Kliewer, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :1016-1023
[65]   Variable expression of CYP and Pgp genes in the human small intestine [J].
Lindell, M ;
Karlsson, MO ;
Lennernäs, H ;
Påhlman, L ;
Lang, MA .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (06) :493-499
[66]   Cytochrome P4502B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity [J].
Loboz, Katarzyna K. ;
Gross, Annette S. ;
Williams, Kenneth M. ;
Liauw, Winston S. ;
Day, Richard O. ;
Blievernicht, Julia K. ;
Zanger, Ulrich M. ;
McLachlan, Andrew J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :75-84
[67]   Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis [J].
Lopez-Cortes L.F. ;
Ruiz-Valderas R. ;
Pompyo V. ;
Aristides A.-G. ;
Gomez-Mateos J. ;
Leon-Jimenez E. ;
Sarasa-Nacenta M. ;
Lopez-Pua Y. ;
Pachon J. .
Clinical Pharmacokinetics, 2002, 41 (9) :681-690
[68]   A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism [J].
Lucas, RA ;
Gilfillan, DJ ;
Bergstrom, RF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (08) :639-643
[69]   Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines - A Report on the Vitrocellomics EU-project [J].
Mandenius, Carl-Fredrik ;
Andersson, Tommy B. ;
Alves, Paula M. ;
Batzl-Hartmann, Christine ;
Bjorquist, Petter ;
Carrondo, Manuel J. T. ;
Chesne, Christophe ;
Coecke, Sandra ;
Edsbagge, Josefina ;
Fredriksson, J. Magnus ;
Gerlach, Joerg C. ;
Heinzle, Elmar ;
Ingelman-Sundberg, Magnus ;
Johansson, Inger ;
Kuppers-Munther, Barbara ;
Mueller-Vieira, Ursula ;
Noor, Fozia ;
Zeilinger, Katrin .
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2011, 39 (02) :147-171
[70]   Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction [J].
Martignoni, Marcella ;
Groothuis, Geny M. M. ;
de Kanter, Ruben .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (06) :875-894